What management advice should I give a patient with anxiety and three‑week mood instability who has been started on lamotrigine 50 mg, hydroxyzine, and trazodone, whose relative reports no improvement and who continues to use marijuana?

Management of Treatment-Resistant Anxiety and Mood Instability with Ongoing Cannabis Use

The current medication regimen is inadequate after 3 weeks, and the patient's continued marijuana use is likely undermining treatment response—you must address cannabis cessation as a priority while reassessing the diagnosis and optimizing pharmacotherapy. 1

Immediate Assessment Priorities

Re-evaluate the Diagnosis

• Three weeks is insufficient time to assess lamotrigine efficacy for mood stabilization, as therapeutic doses typically require 6-8 weeks of titration 2
• Lamotrigine 50 mg is a sub-therapeutic dose for mood disorders; therapeutic ranges are typically 150-300 mg/day for bipolar disorder 2
• Cannabis use can induce anxiety, mood instability, and even psychotic symptoms that mimic primary psychiatric disorders 1
• Consider whether symptoms represent primary anxiety/mood disorder versus cannabis-induced psychiatric symptoms (ICD-10 F12.5) 3

Address Cannabis Use as Primary Barrier

• Cannabis use significantly interferes with treatment response and can worsen anxiety and mood symptoms 1
• Evidence suggests cannabis affects neural circuitry involved in fear regulation and emotional processing 1
• Strongly counsel immediate cessation with specific behavioral strategies and close monitoring 4
• Consider that trazodone prolonged-release (150-300 mg/day) has shown benefit specifically for cannabis use disorder with comorbid anxiety/sleep disturbance 5

Medication Optimization Strategy

Lamotrigine Titration

• Continue lamotrigine titration if bipolar disorder is suspected, but recognize that 50 mg is far below therapeutic range 2
• Standard titration: increase by 25-50 mg every 1-2 weeks to target 150-300 mg/day 2
• Warning: Lamotrigine can induce manic episodes, particularly in bipolar I disorder, manic predominant polarity, or those with history of antidepressant-induced switches 6, 7
• Monitor closely for affective switches, psychotic symptoms, or hallucinations during titration 7

Trazodone Adjustment

• Current trazodone dosing is likely sub-therapeutic for depression/anxiety if used as primary antidepressant 8
• Antidepressant doses of trazodone are typically 150-300 mg/day, not the lower doses used for sleep augmentation 8
• Trazodone may be particularly beneficial given comorbid insomnia, anxiety, and cannabis dependence 5
• Consider increasing to trazodone prolonged-release 150-300 mg/day as monotherapy or primary agent 8, 5
• Trazodone has low risk of weight gain, sexual dysfunction, and anticholinergic effects compared to other antidepressants 8

Hydroxyzine Role

• Hydroxyzine is appropriate for acute anxiety management but should not be sole long-term treatment 9
• Benzodiazepines should be time-limited due to abuse/dependence risk and cognitive impairment 9
• Hydroxyzine is safer than benzodiazepines for longer-term use in anxiety 9

Stepped Care Approach

If Mild-Moderate Anxiety Predominates:

• Optimize trazodone to 150-300 mg/day for antidepressant/anxiolytic effect 8
• Continue hydroxyzine as needed for breakthrough anxiety 9
• Mandatory cannabis cessation with weekly monitoring 1, 5
• Add cognitive behavioral therapy or behavioral activation 10

If Mood Instability/Bipolar Features Predominate:

• Continue lamotrigine titration to therapeutic range (150-300 mg/day) over 6-8 weeks 2
• Monitor closely for manic switches, especially if bipolar I or manic predominant polarity 6
• Consider adding mood stabilizer (lithium, valproate) if manic symptoms emerge 2
• Avoid antidepressant monotherapy if bipolar disorder confirmed, as it may destabilize mood 2

If No Response After 8 Weeks of Optimized Treatment:

• Reassess diagnosis and medication compliance 9
• Consider referral to psychiatry for complex medication management 9
• Evaluate for treatment-resistant depression requiring augmentation strategies 11
• Rule out ongoing substance use as cause of treatment failure 4, 1

Critical Follow-Up Plan

Weekly Monitoring (First Month):

• Assess medication adherence, side effects, and cannabis use status 9
• Monitor for emergent suicidal ideation, especially in young adults on antidepressants 12
• Screen for manic symptoms (irritability, decreased sleep need, increased energy, impulsivity) 6
• Use standardized scales (PHQ-9 for depression, GAD-7 for anxiety) 10

Monthly Reassessment:

• If symptoms persist despite good adherence and cannabis abstinence, alter treatment course 9
• Consider adding psychotherapy, changing medications, or psychiatric referral 10
• Patients with anxiety often avoid follow-through on referrals—proactively address barriers 9

Common Pitfalls to Avoid

• Do not conclude treatment failure at 3 weeks with sub-therapeutic lamotrigine dosing 2
• Do not ignore ongoing cannabis use as primary contributor to treatment resistance 1, 5
• Do not use trazodone at sleep-dose ranges (25-100 mg) when treating depression/anxiety as primary indication 8
• Do not continue ineffective regimen beyond 8 weeks without modification 9
• Do not overlook lamotrigine's potential to induce mania in vulnerable populations 6, 7